RE:RE:On GLP-1 agonists US Senate passes anti-patent thicket billThe US Senate's passing of the anti-patent thicket bill impacts all biotech/pharma companies who previously relied on establishing a patent thicket strategy to protect their market exclusivity. Going forward, the original product will be patentable, while subsequent claims on variations to the origibal product will not.
Consequently, the 13 years of market exclusivity from the date of product approval for novel biologics like ONCY's pelareorep, will give pelareorep the benefit of being able to be combined with I/O agents that may have lost their patent exclusivities, and would be offered together as exclusive doublets, triplets or quadruple therapies, for example.